Proposed changes ICER 2023 value assessment framework-Reference-Cited by-同舟云学术

Proposed changes ICER 2023 value assessment framework

Published:2023-12-21 Issue:4 Volume:3 Page:22-28
ISSN:2782-3784
Container-title:Real-World Data & Evidence
language:
Short-container-title:MyRWD

Author:

Svechkareva I. R.¹^ORCID,Kurylev A. A.²^ORCID

Affiliation:

1. FSBEI HE First St. Petersburg State Medical University named after I.P. Pavlov

2. FSBEI HE First St. Petersburg State Medical University named after I.P. Pavlov; FSBI National Research Center of Oncology named after N.N. Petrov of the Ministry of Health of Russia

Abstract

Since 2006, the Institute for Clinical and Economic Review (ICER) in the United States has assessed the clinical and economic value of innovative medical technologies and made pricing recommendations with the goal of achieving “sustainable access to highly effective treatments for all patients”. The methodological framework developed by ICER assesses the longterm economic value of health interventions and their availability in the shortest possible time.

Publisher

Publishing House OKI

Reference13 articles.

1. Milovanov S.S. Osobennosti nabora patsientov v klinicheskikh issledovaniyakh na primere mezhdunarodnykh mul'titsentrovykh klinicheskikh issledovanii (MMKI). Razrabotka i registratsiya lekarstvennykh sredstv. 2023;12(3):151-168. [Milovanov SS. Patterns of Patient Recruitment in Clinical Studies on the Example of International Multicenter Clinical Studies (IMCTs). Drug development & registration. 2023;12(3):151-168. (In Russ.) https://doi.org/10.33380/2305-2066-2023-12-3-151-168].

2. Malaya I.P. Klinicheskie issledovaniya u pozhilykh: sostoyanie problemy i sovremennye regulyatornye trebovaniya. Rossiiskii zhurnal geriatricheskoi meditsiny. 2021;(1):97-104. [Malaya IP. Clinical trials in geriatrics: actual status and international regulatory guidelines. Russian Journal of Geriatric Medicine. 2021;(1):97-104. (In Russ.) https://doi.org/10.37586/2686-8636-1-2021-97-104].

3. Korobeinikova A.N. Otsenka pryamykh i nepryamykh zatrat v analize «stoimost' bolezni» u bol'nykh fibrillyatsiei predserdii. Meditsinskie tekhnologii. Otsenka i vybor. 2017. 2(28):49-57.

4. Kolbin A.S., Vlodavets D.V., Kurylev A.A., Germanenko O.Yu., Kolbina N.Yu. Otsenka tekhnologii zdravookhraneniya orfannykh zabolevanii. Na primere sotsial'no-ekonomicheskogo bremeni spinal'noi myshechnoi atrofii. Pediatricheskaya farmakologiya. 2021;18(5):408-415. [Kolbin AS, Vlodavets DV, Kurylev AA, Germanenko OYu, Kolbina NYu. Health Technologies Assessment for Orphan Diseases. Example of Social and Economic Burden of Spinal Muscular Atrophy. Pediatric pharmacology. 2021;18(5):408-415. (In Russ.)]. https://doi.org/10.15690/pf.v18i5.2333.

5. Ivanov A.V. Registry kak osnova dlya sbora dannykh i postroeniya dokazatel'stv. Real'naya klinicheskaya praktika: dannye i dokazatel'stva. 2021;1(1):10-15. [Ivanov AV. Registers as the basis for data collection and evidence building. Real-World Data & Evidence. 2021;1(1):10-15.]. https://doi.org/10.37489/2782-3784-myrwd-3.